No Data
AstraZeneca Selloff on China News 'Feels Far Overdone,' Says Barclays
AstraZeneca Raised to Hold From Sell by Deutsche Bank
Daiichi Sankyo/AstraZeneca (AZN.US) received approval in China for the fourth indication of Durvalumab.
Recently, the fourth indication for which the combination development and commercialization of the dequ medical vumab monoclonal antibody developed jointly by Astrazeneca (AZN.US) and Daiichi Sankyo has been approved in China is for the treatment of adults with unresectable or metastatic non-small cell lung cancer with HER2 (ERBB2) activating mutations who have received at least one prior systemic therapy.
Top Gap Ups and Downs on Tuesday: ALAB, PLTR, AZN and More
AstraZeneca's China Business Under Spotlight Amid Fraud Case
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
![Chinese Stocks Surge on Return from Holidays as Euphoria Extends [CSOP Global Market Morning Report]](https://ussnsimg.moomoo.com/sns_client_feed/71451441/20241008/1728367312428-c514003b5c.jpeg/thumb?area=999&is_public=true)
PaulG : 22 00
103704651 OP PaulG :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
22 above today